Core Insights - The collaboration between Junsheng Tai Pharmaceutical and the Chinese Academy of Medical Sciences aims to evaluate the therapeutic potential of the core product HTD1801 for treating chronic kidney disease associated with type 2 diabetes [1][2] - The project has received approval from the Chinese Academy of Medical Sciences, focusing on innovative drug mechanisms and clinical research for diabetes and chronic kidney disease [1] - The partnership leverages the research advantages of the Academy and the company's expertise in metabolic diseases to accelerate clinical progress and enhance product value [1] Product Details - HTD1801 is the core product of Junsheng Tai Pharmaceutical, designed as an oral anti-inflammatory and metabolic regulator targeting the gut-liver system [2] - It features a unique dual mechanism that activates AMPK and inhibits the NLRP3 inflammasome, showcasing its potential in treating multiple comorbidities such as type 2 diabetes, chronic kidney disease, obesity, dyslipidemia, and fatty liver [2] - Over a dozen global clinical trials have demonstrated that HTD1801 can simultaneously improve various health indicators, including blood sugar, blood lipids, kidney function, weight, liver function, and cardiovascular health [2]
君圣泰医药-B(02511)与中国医学科学院医药生物技术研究所共同开展课题合作 探索创新药代谢与肾脏获益潜力